Tysabri Safety Study To Commence Following Lift Of Clinical Hold
Executive Summary
Biogen Idec/Elan's monotherapy safety extension study of its multiple sclerosis therapy Tysabri will help shape FDA's risk management demands for the biologic, assuming it is re-approved